References
- ClemensAFraessdorfMFriedmanJCardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatmentVasc Health Risk Manag2013959961524143109
- HohnloserSHOldgrenJYangSMyocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) trialCirculation2012125566967622215856
- DansALConnollySJWallentinLConcomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trialCirculation2013127563464023271794
- ConnollySJEzekowitzMDYusufSReillyPAWallentinLRandomized evaluation of long-term anticoagulation therapy investigators. Newly identified events in the RE-LY trialN Engl J Med2010363191875187621047252
- ArtangRRomeENielsenJDVidailletHJMeta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin InhibitorsAm J Cardiol20131121219731979 Epub September 25, 201324075284
- DaleBEikelboomJWWeitzJIDabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?J Thromb Thrombolysis201335229530123242974
- LipGYHLaneDADoes warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?Am J Med2010123978578920655037
- UchinoKHernandezAVDabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trialsArch Intern Med2012172539740222231617
- MakKHCoronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trialsBMJ Open201225e001592
References
- HohnloserSHOldgrenJYangSMyocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trialCirculation20121255669676 Epub January 3, 201222215856
- DansALConnollySJWallentinLConcomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trialCirculation20131275634640 Epub December 27, 201223271794
- BorissoffJIOttenJJHeenemanSGenetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent mannerPLoS One201382e5578423409043
- DaleBEikelboomJWWeitzJIDabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?J Thromb Thrombolysis201335229530123242974
- GibsonCMChakrabartiAKMegaJReduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51J Am Coll Cardiol201362428629023602776
- AlexanderJHLopesRDJamesSApixaban with antiplatelet therapy after acute coronary syndromeN Engl J Med2011365869970821780946
- TenYDevlinGBivalirudin in acute coronary syndromes and percutaneous coronary intervention: should we use it?Heart Lung Circ2013221079380023916503
- StegPGMehtaSRPollackCVJrAnticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trialJAMA2013310111145115523995608
- Boehringer IngelheimBoehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations [press release]Ingelheim am RheinBoehringer Ingelheim11192013 Available from: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/19_november_2013_dabigatranetexilate1.htmlAccessed December 04, 2013
- Population Health Research InstituteManagement of Myocardial Injury After Noncardiac Surgery Trial (MANAGE) Available from: http://clinicaltrials.gov/show/NCT01661101. NLM identifier: NCT01661101Accessed December 5, 2013